Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

Exclusion Criteria

• •1. Women who are pregnant or nursing or planning to become pregnant during the study.
• •2. Subjects who have been treated for warts within the 30 days prior to the Baseline Visit (e.g. salicylic acid, azelaic acid, cryotherapy).
• •3. Subjects who have participated in a trial involving any investigational product in the 30 days prior to the Baseline Visit.
• •4. Subjects with chronic or active liver disease, renal impairment, cutaneous or systemic lupus erythematosus, an autoimmune disorder, immunosuppression, or any other disease or medical condition that would interfere with the study or place the subject at unacceptable risk, as determined by the investigator.
• •5. Subjects on immunosuppressive agents that would impact their immune response e.g. cyclosporine, mycophenolate mofetil, azathioprine, etc.
• •6. Subjects who use or have used local/systemic steroids or any other immunosuppressive medication within the 30 days prior to the Baseline Visit.
• •7. Subjects who use or have used systemic or topical retinoids within the 30 days prior to the Baseline Visit.
• •8. Subjects who are unable to comply with study requirements.
• •9. Subjects with other skin diseases like molluscum contagiosum that may confound the evaluation of common warts.
• •10. Subjects who have received treatment for any type of cancer within 5 years of the Baseline Visit, except skin cancer and cervical cancer (in situ) are allowed if at least 1 year before the Baseline Visit.
• •11. Subjects unable to comply with study requirements